Cure or curse? Ambivalent attitudes towards neuroleptic medication in schizophrenia and non-schizophrenia patients

Mental Illness

Volumn 1, Issue 1, 2009, Pages 4-9

  Moritz, Steffen ^a   Peters, Maarten J V ^b   Karow, Anne ^a   Deljkovic, Azra ^a   Tonn, Peter ^a   Naber, Dieter ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Adherence; Antipsychotics; Compliance; Neuroleptics; Schizophrenia; Side effects

Indexed keywords

EID: 77958173836     PISSN: 20367457     EISSN: 20367465     Source Type: Journal    
DOI: 10.4081/mi.2009.e2     Document Type: Article

References (43)

1. Voruganti LP, Baker LK, Awad AG. New generation antipsychotic drugs and compliance behaviour. Curr Opin Psychiatry 2008;21:133-9.
2. Dolder CR, Lacro JP, Dunn LB, Jeste DV. Antipsychotic medication adherence: Is there a difference between typical and atypical agents? Am J Psychiatry 2002;159: 103-8.
3. Byerly MJ, Nakonezny PA, Lescouflair E. Antipsychotic medication adherence in schizophrenia. Psychiatr Clin North Am 2007;30:437-52.
4. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:1209-23.
5. Kahn RS, Fleischhacker WW, Boter H, et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 2008;371:1085-97.
6. Moncrieff J. Does antipsychotic withdrawal provoke psychosis? Review of the literature on rapid onset psychosis (supersensitivity psychosis) and withdrawal-related relapse. Acta Psychiatr Scand 2006;114:3-13.
7. World Health Organization. Adherence to long-term therapies. Evidence for action. Geneva (Switzerland): World Health Organization; 2003.
8. Dolder CR, Lacro JP, Jeste DV. Adherence to antipsychotic and nonpsychiatric medications in middle-aged and older patients with psychotic disorders. Psychosom Med 2003;65:156-62.
9. Finn SE, Bailey JM, Schultz RT, Faber R. Subjective utility ratings of neuroleptics in treating schizophrenia. Psychol Med 1990;20:843-8.
10. Schimmelmann BG, Paulus S, Schacht M, et al. Subjective distress related to side effects and subjective well-being in first admitted adolescents with early-onset psychosis treated with atypical antipsychotics. J Child Adolesc Psychopharmacol 2005;15:249-58.
11. Leucht S, Corves C, Arbter D, et al. Secondgeneration versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009;373:31-41.
12. Naber D, Moritz S, Lambert M, et al. Improvement of schizophrenic patients subjective well-being under atypical antipsychotic drugs. Schizophr Res 2001; 50:79-88.
13. Naber D, Karow A, Lambert M. Subjective well-being under the neuroleptic treatment and its relevance for compliance. Acta Psychiatr Scand 2005;(427):29-34.
14. Karow A, Czekalla J, Dittmann RW, et al. Association of subjective well-being, symptoms, and side effects with compliance after 12 months of treatment in schizophrenia. J Clin Psychiatry 2007;68:75-80.
15. Moritz S. Cognitive dysfunctions. In: Lambert M, Naber D, eds. Current schizophrenia. London: Science Press In press.
16. Fialko L, Garety PA, Kuipers E, et al. A largescale validation study of the Medication Adherence Rating Scale (MARS). Schizophr Res 2008;100:53-9.
17. Heinrichs RW, Zakzanis KK. Neurocognitive deficit in schizophrenia: a quantitative review of the evidence. Neuropsychology 1998;12:426-45.
18. Keefe RSE, Fenton WS. How should DSM-V criteria for schizophrenia include cognitive impairment? Schizophr Bull 2007;33:912-20.
19. Moritz S, Ferahli S, Naber D. Memory and attention performance in psychiatric patients: lack of correspondence between clinician-rated and patient-rated functioning with neuropsychological test results. J Int Neuropsychol Soc 2004;10:623-33.
20. Moritz S, Werner R, von Collani G. The inferiority complex in paranoia readdressed: a study with the Implicit Association Test. Cogn Neuropsychiatry 2006;11:402-15.
21. Buckley PF, Miller BJ, Lehrer DS, Castle DJ. Psychiatric comorbidities and schizophrenia. Schizophr Bull 2009;35:383-402.
22. Freeman D, Garety P, Fowler D, et al. The London-East Anglia randomized controlled trial of cognitive-behaviour therapy for psychosis IV: Self-esteem and persecutory delusions. Br J Clin Psychol 1998;37:415-30.
23. Garety PA. Making sense of delusions. Psychiatry 1992;55:282-91.
24. Morrison AP, Wells A, Nothard S. Cognitive and emotional predictors of predisposition to hallucinations in non-patients. Br J Clin Psychol 2002;41:259-70.
25. Fountoulakis KN, Nimatoudis I, Iacovides A, Kaprinis G. Off-label indications for atypical antipsychotics: A systematic review. Ann Gen Hosp Psychiatry 2004;3:4.
26. Haw C, Stubbs J. Off-label use of antipsychotics: are we mad? Expert Opin Drug Saf 2007;6:533-45.
27. Klingberg S, Schneider S, Wittorf A, et al. Collaboration in outpatient antipsychotic drug treatment: analysis of potentially influencing factors. Psychiatry Res 2008; 161:225-34.
28. Moritz S, Jelinek L. Inversion of the "unrealistic optimism" bias contributes to overestimation of threat in obsessive-compulsive disorder. Behav Cogn Psychother 2009;37:179-93.
29. Moritz S, Laroi F. Differences and similarities in the sensory and cognitive signatures of voice-hearing, intrusions and thoughts. Schizophr Res 2008;102:96-107.
30. Birchwood M, Smith J, Drury V, Healy J, Macmillan F, Slade M. A self-report Insight Scale for psychosis: reliability, validity and sensitivity to change. Acta Psychiatrica Scandinavica 1994;89:62-7.
31. Konings M, Bak M, Hanssen M, van Os J, Krabbendam L. Validity and reliability of the CAPE: a self-report instrument for the measurement of psychotic experiences in the general population. Acta Psychiatr Scand 2006;114:55-61.
32. Velligan DI, Lam F, Ereshefsky L, Miller AL. Perspectives on medication adherence and atypical antipsychotic medications. Psychiatr Serv 2003;54:665-7.
33. Mizrahi R, Rusjan P, Agid O, et al. Adverse subjective experience with antipsychotics and its relationship to striatal and extrastriatal D2 receptors: a PET study in schizophrenia. Am J Psychiatry 2007;164:630-7.
34. Heres S, Schmitz FS, Leucht S, Pajonk FG. The attitude of patients towards antipsychotic depot treatment. Int Clin Psychopharmacol 2007;22:275-82.
35. Patel MX, de Zoysa N, Bernadt M, David AS. A cross-sectional study of patients perspectives on adherence to antipsychotic medication: depot versus oral. J Clin Psychiatry 2008;69:1548-56.
36. Karow A, Naber D. Subjective well-being and quality of life under atypical antipsychotic treatment. Psychopharmacology 2002;162:3-10.
37. Jones SR, Fernyhough C, de-Wit L, Meins E. A message in the medium? Assessing the reliability of psychopathology e-questionnaires. Pers Individ Dif 2008 2008;44:349-59.
38. Ritter P, Lorig K, Laurent D, Matthews K. Internet versus mailed questionnaires: a randomized comparison. J Med Internet Res 2004;15;6:e29.
39. Riva G, Teruzzi T, Anolli L. The use of the internet in psychological research: comparison of online and offline questionnaires. Cyberpsychol Behav 2003; 6:73-80.
40. Chinman M, Young AS, Schell T, et al. Computer-assisted self-assessment in persons with severe mental illness. J Clin Psychiatry 2004;65:1343-51.
41. Lecomte T, Spidel A, Leclerc C, et al. Predictors and profiles of treatment nonadherence and engagement in services problems in early psychosis. Schizophr Res 2008;102:295-302.
42. Moritz S, Woodward TS. Metacognitive training in schizophrenia: from basic research to knowledge translation and intervention. Curr Opin Psychiatry 2007; 20:619-25.
43. Zimmerman G, Favrod J, Trieu VH, Pomini V. The effect of cognitive behavioral treatment on the positive symptoms of schizophrenia spectrum disorders: A meta-analysis. Schizophr Res 2005;77:1-9.